A

argenx

Develops antibody-based therapies for autoimmune diseases

Medical Science Liaison

Full-TimeUpdated on 10/14/2026
No salary listed
Mid
Master's, PharmD, PhD, MD
Brazil
HybridAt least 50% travel required.
Biology & Biotech

About the job

Requirements
  • A scientific, healthcare, or medical degree: MS, PharmD, PhD, MD, RN, or PA.
  • Significant field-based experience in the biopharmaceutical industry in medical affairs.
  • Knowledge of regulations and practices related to industry interactions with healthcare professionals.
  • Ability to accurately and critically evaluate medical and scientific literature, identify strengths and limitations of study design and results, interpret their potential impact on clinical practice and patient outcomes, and translate insights into actionable recommendations that support Medical Affairs strategy development.
  • Ability to achieve results independently and partner with colleagues across functions and geographies.
  • Strong influencing skills to engage effectively with stakeholders and within the company.
  • Ability to quickly understand complex disease areas, treatments, clinical development plans, the healthcare landscape, hospitals, healthcare professionals, the patient journey, and healthcare policy context, including market access processes.
  • Ability to build strategic collaborations with medical experts.
  • Fluent English and Portuguese communication skills, verbal, written, and presentation, and effectiveness in multicultural and multilingual environments.
  • A proven track record of delivering results that meet or exceed targeted objectives.
  • Ability to work collaboratively and effectively within cross-functional teams and networks.
  • Ability to operate adaptably and resiliently in a dynamic, complex, fast-moving, frequently changing environment with ambiguity.
  • Project management skills, including proactive planning, priority setting, and alignment-building.
  • A valid driver’s license.
  • Ability to travel at least 50% of the time.
Responsibilities
  • Develop and continuously maintain high scientific and medical expertise in relevant diseases, products, and development plans, and be recognized internally and externally as an expert.
  • Build, cultivate, and leverage effective relationships with external scientific and medical thought leaders, healthcare professionals, and professional organizations to strengthen collaboration and understand evolving healthcare trends across the therapeutic landscape.
  • Support the development and implementation of Strategic Territory Plans to advance Medical Affairs strategy and drive outcomes within and across the territory.
  • Maintain knowledge of and appropriately implement current local pharmaceutical regulation, and ensure implementation of company policies and procedures.
  • Conduct timely and informative scientific and medical exchanges with external stakeholders that accurately reflect scientific data.
  • Deliver scientific and medical education in a variety of settings, compliantly and in line with medical strategy.
  • Obtain actionable insights on key topics and disseminate them throughout the organization to drive strategy and focus.
  • Coordinate timely and appropriate responses to internal and external medical enquiries, using medical information resources and following regulatory requirements.
  • Attend appropriate local, national, and international meetings and congresses to gather intelligence, develop collaborations, engage in scientific exchange, and share insights within the company.
  • Identify potential high-impact medical research projects and publication opportunities in line with company areas of interest.
  • Systematically capture and disseminate relevant knowledge, including activities and interactions with important contacts, within the company as appropriate.
  • Conduct external interactions in accordance with company objectives, compliance policies and procedures, and established legal, regulatory, and ethical standards.
  • Maintain a close working relationship with all company functions.
  • Support cross-functional teams to ensure operations are patient-focused, respond rapidly to internal and external requests to discuss situations and challenges, and provide medical affairs support to stakeholders.
  • Develop and maintain productive relationships with investigators and clinical study sites, leverage their involvement in company-sponsored research for scientific engagement, and maintain deep knowledge of study design to provide accurate, high-quality scientific support.
Desired Qualifications
  • Clinical experience in neurology, immunology, and/or rare diseases is an advantage.

About the company

argenx develops and markets antibody-based therapies for severe autoimmune diseases. Its medicines work by modulating the immune system through engineered antibodies, notably efgartigimod (VYVGART for generalized myasthenia gravis and VYVGART Hytrulo for CIDP) that influence FcRn pathways. The company differentiates itself through antibody engineering capabilities and a co-creation model with academic and industry partners, plus a pipeline focused on FcRn-, complement-, and target-directed programs across autoimmune indications. Its goal is to provide effective antibody medicines that improve patient outcomes and expand global access through its development and commercial footprint.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Amsterdam, Netherlands

Founded

2008

Get referred to argenx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 8, 2026 FDA approval opened VYVGART to all adult gMG serotypes.
  • August 17, 2026 ALKIVIA met primary endpoint in autoimmune myositis, adding a multibillion-dollar indication.
  • September 29, 2026 AANEM data extended VYVGART into ocular MG and longer-duration CIDP use.

What critics are saying

  • UCB's RYSTIGGO and J&J's nipocalimab attack the same FcRn market by 2027.
  • VYVGART concentration remains extreme; one franchise drove $2.8 billion first-half 2026 sales.
  • If ALKIVIA or upcoming myositis filings disappoint, argenx loses its next blockbuster expansion.

What makes argenx unique

  • VYVGART is first-and-only approved for all adult gMG serotypes after May 8, 2026.
  • argenx scaled $1.5 billion Q2 2026 product sales with 60% year-over-year growth.
  • August 27, 2026 Forte acquisition added FB102, broadening the immunology pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Business Insider
Oct 8th, 2026
Argenx Se (ARGX) receives a Buy from RBC Capital.

Argenx Se (ARGX) receives a Buy from RBC Capital. Oct. 8, 2026, 09:47 PM In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of $1,100.00. According to TipRanks, Issi is an analyst with an average return of -5.6% and a 34.62% success rate. Issi covers the Healthcare sector, focusing on stocks such as Amgen, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $1,182.58 average price target. Based on Argenx Se's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.82 billion and a net profit of $838.82 million. In comparison, last year the company earned a revenue of $947.96 million and had a net profit of $245.36 million Read More on ARGX:

Yahoo Finance
Oct 8th, 2026
Argenx shares drop 15% as Vyvgart fails Sjögren's trial despite celiac drug success

Argenx shares dropped 15% on Thursday after the Dutch biotech announced its blockbuster drug Vyvgart failed to help patients with Sjögren's disease. An independent monitoring board recommended ending the Phase 3 study "for futility" following an interim analysis. The timing surprised analysts, who weren't expecting results until the second half of 2027. Success in Sjögren's could have generated up to $1.4 billion in peak sales for that indication alone. A separate announcement of successful Phase 2 research into a celiac disease drug failed to offset investor concerns. Argenx acquired the medicine, FB102, through a $2.2 billion takeover of Forte Biosciences this year. TD Securities analyst Yaron Werber models $988 million in peak sales for the celiac drug. Despite the setback, Argenx maintains a market cap of around $50 billion. Vyvgart sales reached $1.5 billion in the second quarter alone.

Yahoo Finance
Oct 5th, 2026
10 analysts set Argenx price targets above $1,200 as biotech's revenue surges 60%

Argenx, a biopharmaceutical company with a market capitalisation near $60 billion, has caught the attention of Wall Street analysts. Ten analysts predict the biotech stock will reach at least $1,200 over the next 12 months, up from around $919 as of 2 October 2026. Wells Fargo and UBS set the highest price targets at $1,415 and $1,400 respectively, representing potential gains exceeding 50%. The average price target amongst 21 analysts stands at approximately $1,182, suggesting 29% upside. All but one analyst recommends buying the stock. Argenx's optimism stems from strong performance, delivering $1.5 billion in global product net sales last quarter, up 60% year over year. Its flagship drugs Vyvgart and Vyvgart Hytrulo drive growth, with additional approvals for autoimmune diseases potentially forthcoming.

ReachMD
Sep 30th, 2026
argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026.

argenx to Present New VYVGART Data in MG and CIDP, Plus Pipeline Results, at AANEM 2026. 09/30/2026 Key Takeaways * argenx will present data on its portfolio and pipeline at the AANEM Annual Meeting and the MGFA Scientific Session, September 29 to October 2 in Orlando, Florida, including four oral presentations and dozens of posters. * New VYVGART (efgartigimod) results include deepening improvement in ocular myasthenia gravis (MG), sustained one-year efficacy in anti-AChR antibody-negative generalized MG (gMG), real-world data on earlier treatment, and long-term and switch data in chronic inflammatory demyelinating polyneuropathy (CIDP). * argenx will also present Phase 2 empasiprubart data in multifocal motor neuropathy (MMN) and Phase 1b adimanebart data in DOK7 congenital myasthenic syndrome (CMS). argenx, an Amsterdam-based immunology company, announced it will present clinical, long-term, and real-world data for VYVGART (intravenous efgartigimod alfa-fcab) and VYVGART Hytrulo (subcutaneous efgartigimod alfa and hyaluronidase-qvfc), along with results for two pipeline candidates. Chief Medical Officer Luc Truyen, M.D., Ph.D., said the data show how far the evidence for VYVGART reaches, across years of treatment and into patient populations historically left out of clinical trials. In MG, the company will present three sets of findings: * Ocular MG. In the Phase 3 ADAPT OCULUS study, patient-reported ocular scores on the Myasthenia Gravis Impairment Index (MGII) improved further after two VYVGART cycles beyond the placebo-controlled period. Scores went from -4.5 to -6.8 points in patients with anti-AChR antibodies and from -2.7 to -4.5 points in triple-seronegative patients. The company says the results build on evidence for VYVGART's potential as the first targeted treatment for ocular MG.

Yahoo Finance
Sep 26th, 2026
Argenx stock tipped for 23% gain on $1.5B revenue surge and Vyvgart expansion

Argenx stock has gained roughly 14% year-to-date, with Wall Street analysts projecting a potential 23% upside over the next 12 months. The biotech company has delivered 18 consecutive quarters of revenue growth. In Q2 2026, Argenx's global product net sales surged 60% year over year to $1.5 billion, with a 17% quarter-over-quarter increase. The Vyvgart franchise, treating chronic autoimmune disorders, drives growth following May 2026 FDA approval making it the first treatment for all serotypes of adults with generalised myasthenia gravis. Approximately 24,000 US patients receive treatment for chronic inflammatory demyelinating polyneuropathy, with half not well-managed on current therapy. Argenx reported positive Phase 3 results for Vyvgart in ocular myasthenia gravis earlier this year, with regulatory filing underway.